Will prasugrel supersede clopidogrel for acute coronary syndromes?

Medical Journal of Australia

Volumn 188, Issue 7, 2008, Pages 381-382

  Hankey, Graeme J ^a   Eikelboom, John W ^b,c   Langton, Paul E ^d,e  

^a ROYAL PERTH HOSPITAL   (Australia)

^b HAMILTON GENERAL HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^e UNIVERSITY OF NOTRE DAME   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PRASUGREL; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EDITORIAL; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; RISK REDUCTION; STENT THROMBOSIS; STROKE; THROMBOCYTE AGGREGATION INHIBITION; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY BYPASS GRAFT; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ACUTE CORONARY SYNDROME; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CORONARY ARTERY BYPASS; HEMORRHAGE; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THIOPHENES; TICLOPIDINE;

EID: 46249084177     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2008.tb01678.x     Document Type: Editorial

References (9)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
2. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-1189.
3. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
4. Wiviott SD. Clopidogrel response variability, resistance, or both? Am J Cardiol 2006; 98 (10 Suppl): 18N-24N.
5. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111: 2099-2106.
6. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006; 48: 931-938.
7. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173.
8. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153: 66.e9-66.e16.
9. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.